Toby Capstick, Rhys Hurst, Jennie Keane, Besma Musaddaq
{"title":"支持非结核分枝杆菌肺病患者:确保英国医疗机构的最佳实践。","authors":"Toby Capstick, Rhys Hurst, Jennie Keane, Besma Musaddaq","doi":"10.3390/pharmacy12040126","DOIUrl":null,"url":null,"abstract":"<p><p>Nontuberculous mycobacterial pulmonary disease (NTM-PD) results from opportunistic lung infections by mycobacteria other than <i>Mycobacterium tuberculosis</i> or <i>Mycobacterium leprae</i> species. Similar to many other countries, the incidence of NTM-PD in the United Kingdom (UK) is on the rise for reasons that are yet to be determined. Despite guidelines established by the American Thoracic Society (ATS), the Infectious Diseases Society of America, and the British Thoracic Society, NTM-PD diagnosis and management remain a significant clinical challenge. In this review article, we comprehensively discuss key challenges in NTM-PD diagnosis and management, focusing on the UK healthcare setting. We also propose countermeasures to overcome these challenges and improve the detection and treatment of patients with NTM-PD.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11359432/pdf/","citationCount":"0","resultStr":"{\"title\":\"Supporting Patients with Nontuberculous Mycobacterial Pulmonary Disease: Ensuring Best Practice in UK Healthcare Settings.\",\"authors\":\"Toby Capstick, Rhys Hurst, Jennie Keane, Besma Musaddaq\",\"doi\":\"10.3390/pharmacy12040126\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Nontuberculous mycobacterial pulmonary disease (NTM-PD) results from opportunistic lung infections by mycobacteria other than <i>Mycobacterium tuberculosis</i> or <i>Mycobacterium leprae</i> species. Similar to many other countries, the incidence of NTM-PD in the United Kingdom (UK) is on the rise for reasons that are yet to be determined. Despite guidelines established by the American Thoracic Society (ATS), the Infectious Diseases Society of America, and the British Thoracic Society, NTM-PD diagnosis and management remain a significant clinical challenge. In this review article, we comprehensively discuss key challenges in NTM-PD diagnosis and management, focusing on the UK healthcare setting. We also propose countermeasures to overcome these challenges and improve the detection and treatment of patients with NTM-PD.</p>\",\"PeriodicalId\":30544,\"journal\":{\"name\":\"Pharmacy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11359432/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/pharmacy12040126\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/pharmacy12040126","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
非结核分枝杆菌肺病(NTM-PD)是由结核分枝杆菌或麻风分枝杆菌以外的分枝杆菌引起的机会性肺部感染。与许多其他国家一样,英国 NTM-PD 的发病率也在上升,原因尚不明确。尽管美国胸科学会(ATS)、美国传染病学会(Infectious Diseases Society of America)和英国胸科学会(British Thoracic Society)制定了相关指南,但 NTM-PD 的诊断和管理仍然是一项重大的临床挑战。在这篇综述文章中,我们以英国的医疗环境为重点,全面讨论了 NTM-PD 诊断和管理所面临的主要挑战。我们还提出了克服这些挑战的对策,以改善对 NTM-PD 患者的检测和治疗。
Supporting Patients with Nontuberculous Mycobacterial Pulmonary Disease: Ensuring Best Practice in UK Healthcare Settings.
Nontuberculous mycobacterial pulmonary disease (NTM-PD) results from opportunistic lung infections by mycobacteria other than Mycobacterium tuberculosis or Mycobacterium leprae species. Similar to many other countries, the incidence of NTM-PD in the United Kingdom (UK) is on the rise for reasons that are yet to be determined. Despite guidelines established by the American Thoracic Society (ATS), the Infectious Diseases Society of America, and the British Thoracic Society, NTM-PD diagnosis and management remain a significant clinical challenge. In this review article, we comprehensively discuss key challenges in NTM-PD diagnosis and management, focusing on the UK healthcare setting. We also propose countermeasures to overcome these challenges and improve the detection and treatment of patients with NTM-PD.